PDF(Pubmed)
Abstract：
UNASSIGNED: To assess the functional and anatomical effects of transitioning to conbercept intravitreal injection (IVC) treatment in patients with diabetic macular edema (DME) who had inadequate responses to prior anti-vascular endothelial growth factor (anti-VEGF) injections.
UNASSIGNED: We retrospectively included eyes with persistent DME after at least 3 injections of intravitreal ranibizumab (IVR). The analysis included the assessment of best corrected visual acuity (BCVA) and central macular thickness (CMT) during 6 months after the switch.
UNASSIGNED: A total of 30 patients (30 eyes) were included. CMT dropped sharply from 437.8±40.67μm at baseline to 363.59±45.09,312.52 ± 39.15, 278.51 ± 37.92, and 292.59 ± 38.09 after 1, 2, 3 and 6 months of IVC, respectively (p <0.001). BCVA in log MAR units was significantly improved from 0.73±0.15 at baseline to 0.50±0.09,0.46±0.72, 0.40±0.06 and 0.48±0.04 after 1, 2, 3 and 6 months, respectively (p <0.001).
UNASSIGNED: Switching to Conbercept effectively improved visual and anatomical structure in DME patients who had not responded satisfactorily to previous anti-VEGF injections.
UNASSIGNED: We retrospectively included eyes with persistent DME after at least 3 injections of intravitreal ranibizumab (IVR). The analysis included the assessment of best corrected visual acuity (BCVA) and central macular thickness (CMT) during 6 months after the switch.
UNASSIGNED: A total of 30 patients (30 eyes) were included. CMT dropped sharply from 437.8±40.67μm at baseline to 363.59±45.09,312.52 ± 39.15, 278.51 ± 37.92, and 292.59 ± 38.09 after 1, 2, 3 and 6 months of IVC, respectively (p <0.001). BCVA in log MAR units was significantly improved from 0.73±0.15 at baseline to 0.50±0.09,0.46±0.72, 0.40±0.06 and 0.48±0.04 after 1, 2, 3 and 6 months, respectively (p <0.001).
UNASSIGNED: Switching to Conbercept effectively improved visual and anatomical structure in DME patients who had not responded satisfactorily to previous anti-VEGF injections.
摘要：
评估糖尿病性黄斑水肿（DME）患者接受康柏西普玻璃体腔注射（IVC）治疗的功能和解剖学影响，这些患者对之前的抗血管内皮生长因子（抗VEGF）注射反应不足。
■我们回顾性纳入了至少3次玻璃体内注射雷珠单抗（IVR）后患有持续性DME的眼睛。分析包括在转换后6个月内评估最佳矫正视力（BCVA）和中央黄斑厚度（CMT）。
■共包括30例患者(30只眼)。在IVC的1、2、3和6个月后，CMT从基线的437.8±40.67μm急剧下降至363.59±45.09,312.52±39.15,278.51±37.92和292.59±38.09，分别(p<0.001)。在1、2、3和6个月后，以对数MAR单位表示的BCVA从基线时的0.73±0.15显著提高到0.50±0.09、0.46±0.72、0.40±0.06和0.48±0.04，分别(p<0.001)。
■转换为Conbercept可有效改善DME患者的视觉和解剖结构，这些患者对先前的抗VEGF注射反应不满意。
■我们回顾性纳入了至少3次玻璃体内注射雷珠单抗（IVR）后患有持续性DME的眼睛。分析包括在转换后6个月内评估最佳矫正视力（BCVA）和中央黄斑厚度（CMT）。
■共包括30例患者(30只眼)。在IVC的1、2、3和6个月后，CMT从基线的437.8±40.67μm急剧下降至363.59±45.09,312.52±39.15,278.51±37.92和292.59±38.09，分别(p<0.001)。在1、2、3和6个月后，以对数MAR单位表示的BCVA从基线时的0.73±0.15显著提高到0.50±0.09、0.46±0.72、0.40±0.06和0.48±0.04，分别(p<0.001)。
■转换为Conbercept可有效改善DME患者的视觉和解剖结构，这些患者对先前的抗VEGF注射反应不满意。
